CERo Therapeutics Holdings, Inc. (CERO) Research

CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.

Market snapshot

Symbol
CERO
Price
$0.01
Day change
+8.91%
Market cap
$13.3K
P/E ratio
-0.02x
52-week range
0.009-13.14
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BriaCell Therapeutics Corp. Warrant (BCTXZ)
  • BioVie Inc. (BIVI)
  • PMGC Holdings Inc. (ELAB)
  • Galmed Pharmaceuticals Ltd. (GLMD)
  • Liminatus Pharma, Inc. Class A Common Stock (LIMN)
  • Moolec Science S.A. (MLEC)
  • NKGen Biotech, Inc. Common Stock (NKGN)
  • Ocean Biomedical, Inc. (OCEA)

Recent insider activity

  • Francois Eric — A-Award (1823278 shares) on 2026-03-04
  • Francois Eric — trade (0 shares) on 2026-02-13
  • Rolfe Lindsey — A-Award (690900 shares) on 2026-01-07
  • LAPORTE KATHLEEN — A-Award (690900 shares) on 2026-01-07
  • Pierce Kristen — A-Award (1612099 shares) on 2026-01-07

Open CERo Therapeutics Holdings, Inc. (CERO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.